Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012;17(2):154-6.
doi: 10.1634/theoncologist.2011-0382. Epub 2012 Jan 27.

Phase II studies in soft tissue sarcoma: time for reappraisal

Stefan Sleijfer  1
Affiliations
Comment

Phase II studies in soft tissue sarcoma: time for reappraisal

Stefan Sleijfer. Oncologist. 2012.

Abstract

A phase II study with sorafenib in patients with angiosarcoma conducted by the French Sarcoma Group, and published in this issue of The Oncologist, is evaluated. The importance of proper design and conduct of phase II trials is stressed.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Stefan Sleijfer: None.

Comment on

References

    1. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther. 2010;10:249–260. - PubMed
    1. Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: A phase II trial from the French Sarcoma Group (GSF/GETO) The Oncologist. 2012;17:260–266. - PMC - PubMed
    1. Van der Graaf WTA, Blay J, Chawla SP, et al. PALETTE: A randomized, double-blind, phase III trial of pazopanib versus placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—an EORTC STBSG Global Network Study (EORTC 62072) J Clin Oncol. 2011;29(suppl) Abstract LBA10002. - PubMed
    1. Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–3140. - PMC - PubMed
    1. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175–7179. - PMC - PubMed